2 terminated. 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Terminated 2 |
| Phase 2 | 1 | Terminated 1 |
Follow niraparib: new trials by email Literature Review of niraparib trials Research Report on niraparib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer External Beam Radiation, Niraparib, Vaginal high-dose rate brachytherapy - Endometrial Carcinoma, P53 Mutation | Phase 2 / Phase 3 | Terminated | University Health Network, Toronto | 11 | 2020-11-17 | 2025-08-12 |
| A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients niraparib, Physician's choice - Neoplasms, Breast, Carcinoma of Breast | Phase 3 | Terminated | Tesaro, Inc. | 216 | 2014-02-25 | 2022-11-15 |
Breast Neoplasms (1) · Cystadenocarcinoma, Serous (1) · Endometrial Neoplasms (1) · Ovarian Neoplasms (1)
Tesaro, Inc. (1) · University Health Network, Toronto (1)
Canada (2) · Belgium (1) · France (1) · Greece (1) · Hungary (1) · Iceland (1) · Israel (1) · Italy (1) · Netherlands (1) · Poland (1) · Portugal (1) · Spain (1) · United Kingdom (1) · United States (1)
Amit Oza, MD (1)